If you are diagnosed with cancer, don’t avoid it. Get treated and stay safe.

Ovarian Cancer is cancer that starts in the ovaries and although it starts there, it does have potential to spread. The exact cause for ovarian cancer is unknown, but is well known that DNA mutation is primary cause of any type of cancer. This cancer is the second most common type of cancer among women across the world, while fifth leading cause of  death related to cancer like disease. Immunotherapy may helps to patients to receive a high quality treatment for the cancer.  

Ovarian Cancer is said to be the 10th most common cancer in women and is more likely to lead to death than any other cancer that affects a woman's reproductive system (ranking fifth in cancers that kill women). Ovarian Cancer is known as the silent killer because most times symptoms go unnoticed and unattended too. Generally, the most serious symptoms occur in the late stages of ovarian cancer. Ovarian cancer is rarely diagnosed in its early stages.

www.gapsos.com

It is estimated that about 3 out of 4 women survive ovarian cancer after a year’s diagnosis. About half of the women with ovarian cancer live longer than 5 years, especially if they are diagnosed and treated early.

It is important to know the symptoms of ovarian cancer so that you will be able to detect it early if possible. Several symptoms are notified that involve bloating, abdominal pain, vaginal bleeding, change in menstrual cycle, pelvic pain, nausea or vomiting, back pain that increases constipation, indigestion, swollen abdomen or belly, while decrease in appetite, and increase in bathroom use, increase in hair growth, and an increase or decrease in weight gain.

In immunotherapy, various types of immunotherapeutic cancer agents are involved like monoclonal antibody drugs, therapeutic vaccines, and adoptive T cell therapy. Bevacizumab is a monoclonal antibody drug has received approval by the Food and Drug Administration (FDA) for the treatment of this cancer in the combination with ADC,Topotecan, and  Paclitaxel. FDA concludes none of the contraindication with this drug, while some warnings are mentioned like hemorrhage and gastrointestinal perforations. Some common adverse effects are observed like headache and back pain.Much more immunotherapeutic cancer agents are under evaluation for FDA approval via clinical trials such as Ipilimumab, MORAb-003, OVAX,Natural killer cells, and NY-ESO-1 reactive.